Spero therapeutics announces fourth quarter and full year 2022 operating results and provides business update

Initiated proof-of-concept phase 2 trial of spr720 in nontuberculous mycobacterial pulmonary disease (ntm-pd); top line data expected in 1h 2024

SPRO Ratings Summary

SPRO Quant Ranking